PI: Daniela Kandioler, M.D., MBA
Associate Professor for Surgery
Lab Location: AKH, Level 8, G1.12
E-Mail: daniela.kandioler@meduniwien.ac.at
Phone: +43 1 40400 5621/ 6848
www.p53.at
Research focus
Over- and undertreatment is the main clinical challenge of today’s cancer treatment. To significantly advance cancer survival, we have to identify the most effective treatment for the individual patient.
We claim that the p53 gene could be used as a global predictor for response and resistance to chemotherapy.
The major goal of our projects is to pave the way for routine clinical application of this marker.
Response Prediction
Fifty percent of patients currently do not benefit from standard cancer treatment. P53 is crucially involved in pathways determining cell death in response to treatment, and is at the same time the most frequently mutated gene in human cancer. Thus, a defect in the p53 pathway causes resistance to chemotherapy and radiation.
During the last years, we could consistently demonstrate the relation between the p53 genotype and response to cancer therapies in different tumours.
Prognosis
Prognostic factors influence treatment decisions, estimating the likelihood of recovering from disease or the chance of the disease coming back.
In cancer patients, the most important, clinically used prognostic factor is the involvement of lymph nodes.
Lymph nodes that are staged microscopically as tumour free can be analysed more precisely using molecular techniques. A p53 mutation of the primary cancer can serve as marker to search for micrometastases in lymph nodes.
Methodological Research
Due to uncoordinated application of different, insensitive p53 analysis methods and lack of standards, the literature appears to be inconsistent concerning the prognostic and predictive value of p53. Our research projects are based on complete sequencing of the p53 gene and therefore provide most sensitive and specific information concerning the p53 genotype.
Research activities
Sponsored Clinical Trials
| Clinical Phase | Marker trial type | Cancer /study synonym | Type of treatment | Study status |
|---|---|---|---|---|
| Prospective randomized phase III | Phase III predictive marker trial | pANCHO / p53 adjusted neoadjuvant chemotherapy for potentially resectable oesophageal cancer (NCT00525200) | neoadjuvant ct + surgery | recruiting |
| Prospective phase II | Phase III predictive marker trial | PART1 / p53 adapted preoperative radiotherapy for T2 and T3 rectal cancer | radiation | recruiting |
| Prospective phase II | Phase III predictive marker trial | p53 adapted induction chemotherapy in NSCLC | neoadjuvant ct + surgery | finished recruitment |
| Prospective phase II | Phase II marker trial | oesophageal cancer | neoadjuvant ct + surgery | ASCO 2007 |
| Prospective phase II | Phase II marker trial | rectal cancer | neoadjuvant ct + surgery | published Ann Surg 2006 |
| Prospective randomized cohort | Phase III prognostic/predictive marker trial | colorectal liver metastases | neoadjuvant ct + surgery / surgery only |
manuscript in preparation |
| Prospective randomized cohort | Phase II marker trial | lung cancer | neoadjuvant ct + surgery | published JTCVS 2008 |
| Prospective randomized cohort | Phase II marker trial | Studie 90/ colon cancer | adjuvant ct | manuscript in preparation |
| Observational | Phase I marker trial | lung cancer | neoadjuvant ct + surgery | published JTCVS 1999 |
| Observational | Phase I marker trial | oral cancer | neoadjuvant ct + surgery | manuscript in preparation |
| Observational | Phase I marker trial | ovarian cancer | neoadjuvant ct + surgery | manuscript in preparation |
| Observational | Phase I marker trial | breast cancer | neoadjuvant ct + surgery | published Clin Canc Res 2000 |
Cooperations
| Partner | Title |
|---|---|
| Christine Brostjan MUW, Dept. of Surgery, Research Laboratories |
Analysis of Angiogenesis Parameters in the context of the PART-1 Trial |
| Christine Mannhalter MUW, Department of Laboratory Medicine |
Genetic variants predicting 5-FU toxicity |
| Rainer Schmid MUW, Department of Radiotherapy |
Radiotherapy in the context of the PART1 trial |
| Christiane Kulinna-Cosentini MUW, Department of Radiology |
Advanced MRT Protocol and CT Protocol for rectal cancer |
| Christos Perisanidis MUW, Dept. of Cranio-, Maxillofacial and Oral Surgery |
p53 genotype in oral cancer. |
| Bettina Grasl-Kraupp MUW, Institute of Cancer Research |
Hepatocarcinogenesis |
| Magali Olivier International Agency for Research on Cancer (IARC/CIRC), Lyon, France |
p53 mutation database |